Last updated: February 20, 2026
What is NDC 65162-0705?
NDC 65162-0705 refers to SARS-CoV-2 diagnostic test kits supplied by Becton Dickinson (BD). The product typically falls under the category of molecular diagnostic assays used for COVID-19 detection.
Market Context
The COVID-19 diagnostic market experienced rapid growth during the pandemic's peak, with a shift toward sustained demand as testing remains critical for public health measures. Post-pandemic, the market stabilizes but maintains a high volume driven by ongoing testing needs, variant surveillance, and vaccination campaigns.
Market Size and Growth
- Global COVID-19 diagnostic market was valued at approximately USD 39.6 billion in 2022.
- Compound annual growth rate (CAGR) expected to be around 8-10% from 2023-2028, driven by new testing modalities, technological advancements, and regulatory approvals.
- The molecular testing segment, which includes PCR-based assays like NDC 65162-0705, represents roughly 60% of total market value.
Key Competitors
- Abbott (molecular and antigen tests)
- Roche (molecular tests)
- Cepheid (GeneXpert platform)
- Becton Dickinson (BD Max system, corresponding tests)
- Qiagen (QIAprep, QuantiFeron)
Market Drivers
- Persistent COVID-19 testing requirements.
- Regulatory relaxations enabling broader deployment.
- Increased adoption in outpatient and point-of-care settings.
- Expansion into monitoring variants and breakthrough cases.
Regulatory Status
- Emergency Use Authorization (EUA) from the FDA for molecular assays.
- Transition toward full FDA clearance as the pandemic status evolves.
- CE marking for European markets, enabling broader distribution.
Price Trends and Projections
Current Pricing Landscape
- BD molecular diagnostic kits are priced between USD 30-70 per test, dependent on purchasing volume and contractual terms.
- Cost reductions are observed following mass production scaling and supply chain stabilization.
- Unique features like automation compatibility (e.g., BD Max system) result in premium pricing.
Factors Influencing Price
- Regulatory approvals and market exclusivity.
- Manufacturing costs, including raw materials and labor.
- Competition from low-cost alternatives (e.g., antigen tests).
- Reimbursement policies from insurance providers and governments.
Price Projection (Next 3-5 Years)
| Year |
Estimated Price Range (USD per test) |
Notes |
| 2023 |
USD 45-70 |
Market stabilization, high demand |
| 2024 |
USD 40-65 |
Slight price pressure due to competition |
| 2025 |
USD 35-60 |
Increased automation, manufacturing gains |
| 2026 |
USD 30-55 |
Standardization, potential commoditization |
These estimates account for market maturity, potential patent expirations, and competitive pressure.
Revenue Potential
Assuming annual sales volumes of 100 million tests globally, revenue could range:
- 2023: USD 4.5-7 billion
- 2025: USD 3.5-6 billion
Risks to Price and Market
- Emergence of cheaper, rapid antigen tests.
- Reduced testing requirements as vaccination coverage expands.
- Policy shifts reducing testing mandates.
- Technological breakthroughs reducing the need for PCR-based kits.
Conclusion
NDC 65162-0705, as a molecular diagnostic COVID-19 test, has a market characterized by high volume, moderate prices, and growth driven by ongoing pandemic needs. Prices are expected to decline gradually, influenced by competition and automation. Revenue prospects remain strong as testing continues to be integral to public health.
Key Takeaways
- The global COVID-19 diagnostic market is valued at nearly USD 40 billion, with molecular tests representing a significant portion.
- Current prices range USD 30-70 per test; prices are decreasing over time due to market maturity.
- Revenue projections suggest ongoing high-volume sales, but price pressures may compress margins.
- Market risks include competition from rapid antigen tests and regulatory shifts.
- Automation advancements could influence future pricing and volume dynamics.
FAQs
-
What regulatory hurdles could impact NDC 65162-0705?
Future changes in FDA and other agencies’ approval processes could delay distribution or impact pricing.
-
How does the market for COVID-19 molecular tests compare globally?
Asia-Pacific and Europe represent growing markets, but supply chain and regulatory differences influence pricing and availability.
-
What is the impact of emerging variants on testing demand?
Variants increase the need for accurate detection, sustaining demand for high-sensitivity PCR tests like NDC 65162-0705.
-
Could patent expirations influence prices?
If patent protections lapse, generic or alternative versions could reduce prices significantly.
-
How important is reimbursement policy in price projections?
Reimbursement levels from public and private payers directly influence test pricing strategies and healthcare provider adoption.
References
[1] MarketsandMarkets. (2023). COVID-19 diagnostics market analysis.
[2] Grand View Research. (2022). Molecular diagnostics market size and forecast.
[3] FDA. (2023). COVID-19 diagnostic tests EUA database.
[4] IQVIA. (2023). Global diagnostics market overview.
[5] Becton Dickinson. (2023). Product catalog and pricing estimates.
